Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07444320

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07444320
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Croatia, Czechia, Hong Kong SAR China, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07444320. Allocation not applicable; no masking; primary purpose treatment. Start 2026-02-12 (actual); primary completion 2028-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
Acronym
IMPULSE-EVO
Condition
Paroxysmal Atrial Fibrillation
Condition
Persistent Atrial Fibrillation
Intervention (Device)
FARAPULSE™ Pulsed Field Ablation (PFA) System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07444320
Content hash
57a79cd4e94fc03d4dcd4e603e01b724d16aa5cd1f82a8edd684f941a052f095